Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549751 · ClinicalTrials.gov registry record · Phase 1
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Marker Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT06549751 is a Phase 1 study that has not yet begun recruiting, run by Marker Therapeutics. The registered enrollment target is 38 participants.
The verdict
NCT06549751, a Phase 1 study, has not yet begun recruiting, sponsored by Marker Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.
Interventions
- DRUG MT-601 dose 200 million cells
- DRUG MT-601 dose 400 million cells
- DRUG MT-601 dose 800 million cells
- DRUG MT-601 dose 1200 million cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-07-16 |
| Est. Completion | 2028-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06549751
The ClinicalTrials.gov registry entry for NCT06549751 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MT-601 dose 200 million cells is the first listed.
NCT06549751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06549751 about?
NCT06549751 is a clinical study titled "MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer". The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of r...
What is the current status of trial NCT06549751?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2026-07-16. Estimated completion is 2028-09-16.
What interventions are being tested in trial NCT06549751?
The interventions under investigation include: MT-601 dose 200 million cells (DRUG), MT-601 dose 400 million cells (DRUG), MT-601 dose 800 million cells (DRUG), MT-601 dose 1200 million cells (DRUG).
Who is sponsoring clinical trial NCT06549751?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.